Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
28.08. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue | 3 | GlobeNewswire (USA) | ||
07.08. | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the second quarter 2025 | 313 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 7 August 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the second quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
06.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | 289 | Xetra Newsboard | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
01.08. | Modus Therapeutics Holding AB: Modus Therapeutics on track to initiate Part 2 of Phase IIa sevuparin study in CKD-related anemia | 286 | GlobeNewswire (Europe) | Stockholm, Sweden - 1 August 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that dose levels for Part 2 of its ongoing Phase IIa clinical study of sevuparin in patients with chronic... ► Artikel lesen | |
29.07. | Modus Therapeutics Holding AB: Extraordinary General Meeting in Modus Therapeutics Holding AB (publ) | 121 | GlobeNewswire (Europe) | Modus Therapeutics' Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
To amend the company's articles of association in order to increase the limits of the company's... ► Artikel lesen | |
14.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin | 252 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part... ► Artikel lesen | |
08.07. | Modus Therapeutics Holding AB: Modus Therapeutics completes enrollment in Part 1 of the Phase IIa sevuparin study in chronic kidney disease with anemia | 167 | GlobeNewswire (Europe) | Stockholm, Sweden - 8 July 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that patient enrollment in Part 1 of its ongoing Phase IIa study evaluating sevuparin for the treatment... ► Artikel lesen | |
27.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million | 1 | GlobeNewswire (USA) | ||
14.05. | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the first quarter 2025 | 438 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 14 May 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the first quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
02.04. | Modus Therapeutics Holding AB: Modus Therapeutics opens second study site in ongoing Phase IIa CKD-anemia study | 148 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - April 2, 2025: Modus Therapeutics Holding AB ("Modus"), a company developing innovative treatments for patients with significant unmet medical needs, today announced the opening... ► Artikel lesen | |
20.02. | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2024 | 140 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 20 February 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes the year-end report for 2024. The report is available as an attached document and on the company's... ► Artikel lesen | |
20.11.24 | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for the third quarter 2024 | 126 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 20 November 2024: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter 2024. The report is available as an attached document... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NANOREPRO | 1,675 | -4,56 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
MARINOMED BIOTECH | 18,950 | +3,27 % | Original-Research: Marinomed Biotech AG (von GBC AG): Kaufen | Original-Research: Marinomed Biotech AG - von GBC AG
01.10.2025 / 14:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
REPLENISH NUTRIENTS | 0,078 | -13,47 % | Replenish Nutrients secures licensing deal with MJ Ag Solutions Ltd | ||
SANA BIOTECHNOLOGY | 4,115 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
I-MAB | 3,740 | -0,53 % | I-Mab - 6-K, Report of foreign issuer | ||
GENEURO | 0,035 | +0,57 % | GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium | Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court... ► Artikel lesen | |
ADMA BIOLOGICS | 13,990 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
ARCELLX | 85,21 | +0,98 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
CG ONCOLOGY | 38,000 | -0,24 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
QIAGEN | 40,155 | +0,06 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
GALECTO | 17,990 | 0,00 % | What's Going On With Nano-Cap Galecto Stock On Tuesday? | ||
ARVINAS | 9,300 | -3,23 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
COGENT BIOSCIENCES | 15,440 | -2,89 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
BIONTECH | 91,00 | 0,00 % | Pfizer prescht nach vorne, BioNTech gerät unter Druck, Eli Lilly feiert eine neue Zulassung und AstraZeneca zieht es nach New York | Wieder einmal überschlagen die Dinge sich in der US-Politik, wobei das Thema Gesundheit eine wichtige Rolle spielt. Reibereien über die staatliche Gesundheitsfürsorge gelten als einer der Hauptgründe... ► Artikel lesen | |
DISC MEDICINE | 67,89 | -2,01 % | Mona Ashiya verlässt Verwaltungsrat von Disc Medicine - Gremium auf acht Mitglieder verkleinert |